Voriconazole Plasma Concentrations in Immunocompromised Pediatric Patients Vary by <i>CYP2C19</i> Diplotypes

Abstract

Younger age and the presence of CYP2C19 gain-of-function alleles were associated with subtherapeutic voriconazole concentrations. Starting doses based on age and CYP2C19 status could increase the number of patients achieving therapeutic voriconazole exposure.